Skip to main content

Abaxx to Launch Silver Singapore Futures on May 22, 2026

New 1,000 oz, four-nines silver contract expands Abaxx’s precious metals product suite TORONTO and SINGAPORE, May 18, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company and majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today announced that Abaxx Exchange will launch Abaxx Silver Singapore futures on May 22, 2026, expanding Abaxx’s precious metals product suite. The Abaxx Silver Singapore futures contract is purpose-built for the commercial requirements of the global industrial silver market, providing standardized reference pricing and risk management tools aligned with physical market practices. The contract is...

Continue reading

IREN Acquires Awaken to Support Global Brand Growth

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (“IREN”) today announced the acquisition of Awaken, a creative and media agency specializing in content strategy and brand development for high-growth companies. As part of the transaction, Awaken will cease independent operations and senior members of the team will join IREN under executive employment agreements, including Founder and CEO Chris Parker, who will lead IREN’s brand and marketing strategy. Awaken has served as IREN’s lead external marketing partner, supporting the Company’s AI Cloud growth initiatives. Bringing the team in-house reflects IREN’s focus on strengthening brand awareness as IREN expands into new regions and customer segments. As IREN scales across North America, Europe and APAC, the Awaken team will play a central role in building...

Continue reading

Schouw & Co. share buy-back programme, week 20 2026

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount DKK    Accumulated until 8 May 2026 128,283 667.37 85,611,680    Monday, 11 May 2026 1,000 665.00 665,000    Tuesday, 12 May 2026 1,000 659.00 659,000    Wednesday, 13 May 2026 1,000 667.37 667,369    Thursday, 14 May 2026 – – –    Friday,...

Continue reading

Brady Corporation Reports Record Adjusted EPS in its Fiscal 2026 Third Quarter and Raises its Fiscal 2026 Adjusted EPS Guidance

Sales for the quarter increased 13.8 percent compared to the same quarter of the prior year. Organic sales increased 8.2 percent, acquisitions increased sales 2.1 percent and foreign currency translation increased sales 3.5 percent. Diluted EPS increased 11.0 percent to $1.21 in the third quarter of fiscal 2026 compared to $1.09 in the same quarter of the prior year. Adjusted Diluted EPS* increased 23.0 percent to $1.50 in the third quarter of fiscal 2026 compared to $1.22 in the same quarter of the prior year. Net cash provided by operating activities increased to $78.2 million in the third quarter of fiscal 2026 compared to $59.9 million in the third quarter of last year. GAAP earnings per diluted Class A Nonvoting Common share guidance for the year ending July 31, 2026 was adjusted from the previous range of $4.62 to $4.82 per share...

Continue reading

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

Key highlights from the first quarter of operations under the expanded management team include the following:Anticipated FDA decision on the Company’s ANDA for Preservative-Free Ketamine in Q3 2026, with favorable preliminary determinations already received from the FDA Office of Generic Drugs on bioequivalence, labeling, drug product, drug substance, and safety. Initiation of commercial manufacturing of Ketamine at the 1 million dose per month level with recent FDA inspection of the manufacturing facility and granting of inspection status consistent with launch of an ANDA drug. Completed a Type C meeting with the FDA Division of Psychiatry Products and CDER leadership, in which the Agency expressed openness to existing clinical trial data and Real World Evidence supporting approval without additional trials. Presidential Executive...

Continue reading

Onfolio Holdings Inc. Announces Q1 2026 Financial Results and Provides Corporate Update

Conference Call to Discuss Q1 2026 Results Scheduled for Today at 8:00 a.m. ET WILMINGTON, Del., May 18, 2026 (GLOBE NEWSWIRE) — Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTC: ONFOP) (“Onfolio” or the “Company”), an owner-operator of cash-generative online businesses, announces financial results for the first quarter ended March 31, 2026. Recent Corporate HighlightsActivated acquisition program and will target the acquisition of between $5 million and $10 million in aggregate annual adjusted EBITDA before the end of 2026. Secured a $100 million equity financing facility in April 2026 to accelerate acquisition strategy. Regained compliance with Nasdaq Listing Rule 5550(a)(2) as of May 1, 2026.First Quarter 2026 Financial HighlightsRevenue was $1.87M vs. $2.81M in Q1 2025 Gross profit decreased 46% to $0.92M, or 49% of...

Continue reading

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026.  Independent, blinded biomechanical gait analyses of the CONNECT SCI study designed to differentiate genuine neural recovery from compensatory movement remain ongoing, with results anticipated in 2Q 2026. Successfully listed on Nasdaq under the symbol ‘NGEN’ on January 8, 2026, and voluntarily delisted from the TSX Venture Exchange. Strengthened leadership team with three senior appointments to support late-stage clinical development and Nasdaq listing.VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen” or the “Company”) (NASDAQ: NGEN),...

Continue reading

BingEx Secures Strategic Investment from HLID to Accelerate Drone Delivery

BEIJING, May 18, 2026 (GLOBE NEWSWIRE) — BingEx Limited (“BingEx” or the “Company”) (Nasdaq: FLX), a leading on-demand dedicated courier services provider in China (branded as “FlashEx”), today announced that its wholly-owned subsidiary has recently signed a strategic investment agreement with Hangzhou Low-Altitude Industry Development Co., Ltd. (“HLID”). Upon completion of the investment, FlashEx will become one of the first on-demand delivery companies in Hangzhou to receive strategic support from the city’s low-altitude industry platform, marking a meaningful step in the Company’s expansion into drone delivery and low-altitude logistics. FlashEx is one of China’s earliest and largest on-demand dedicated courier service providers, with more than a decade of experience in intra-city delivery and a fulfillment network covering...

Continue reading

iQIYI Announces First Quarter 2026 Financial Results

BEIJING, May 18, 2026 (GLOBE NEWSWIRE) — iQIYI, Inc. (Nasdaq: IQ) (“iQIYI” or the “Company”), a leading provider of online entertainment video services in China, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsTotal revenues were RMB6.23 billion (US$902.5 million1), decreasing 13% year over year. Operating loss was RMB228.4 million (US$33.1 million) and operating loss margin was 4%, compared to operating income of RMB341.9 million and operating income margin of 5% in the same period in 2025. Non-GAAP operating loss2 was RMB148.6 million (US$21.5 million) and non-GAAP operating loss margin was 2%, compared to non-GAAP operating income of RMB458.5 million and non-GAAP operating income margin of 6% in the same period in 2025. Net loss attributable to iQIYI...

Continue reading

EHang Provides Investors Q&A regarding Form 6-K/A

GUANGZHOU, China, May 18, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), a global leader in advanced air mobility (“AAM”) technology, furnished a Form 6-K/A on May 15, 2026 (the “Form 6-K/A”) to provide corrected unaudited interim financial information for the second quarter, third quarter, and fourth quarter and the full fiscal year ended December 31, 2025. In response to questions from investors regarding the Form 6-K/A, the Company has provided an investor Q&A on its Investor Relations webpage at: https://ir.ehang.com/6-ka-qa. Note: This release provides supplemental background only. It does not amend or supersede any information in the Company’s Form 20-F for 2025. For a full reconciliation of these adjustments and corrected financial information, please refer to the Form 6-K/A...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.